对于头部和部癌症的粒子疗法的开放问题
Romelie Rieu1, Dawn Carnell2, Melvin L K Chua3
1Department of Head and Neck Oncology, The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
Otolaryngologic clinics of North America
|November 21, 2025
概括
颗粒疗法可以降低头癌的正常组织辐射剂量,可能降低毒性. 这项研究检查了粒子疗法交付,生物学和患者选择的不确定性,以改善结果.
科学领域:
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- 颗粒疗法提供了一个独特的深度剂量配置.
- 这可能会减少与传统放射治疗相比,正常组织的辐射.
- 它有可能在癌症治疗中增加剂量或降低毒性.
研究的目的:
- 评估与成人头癌粒子治疗相关的不确定性.
- 评估这些不确定性对治疗结果的影响.
主要方法:
- 考虑粒子交付和验证中的不确定性.
- 放射生物学的不确定性分析.
- 对患者选择因素的评估.
主要成果:
- 粒子治疗的布拉格峰值允许精确的剂量沉积.
- 潜在的保护邻近的器官处于危险之中.
- 在量化和减轻不确定性方面仍然存在挑战.
结论:
- 颗粒疗法是治疗头癌的一个有前途的方法.
- 解决分娩,放射生物学和患者选择方面的不确定性对于临床实施至关重要.
- 需要进一步的研究来优化治疗规划和治疗.
相关概念视频
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K